<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02328716</url>
  </required_header>
  <id_info>
    <org_study_id>EC-GC/AD-01/11</org_study_id>
    <secondary_id>2011-001715-31</secondary_id>
    <nct_id>NCT02328716</nct_id>
  </id_info>
  <brief_title>Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma</brief_title>
  <acronym>CARCINOHIPEC</acronym>
  <official_title>Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to Investigate whether the administration of HIPEC with
      Cisplatin (75 milligrams per square meter of body surface) after surgical cytoreduction in
      women with ovarian, tubal or primary peritoneal carcinoma increased disease-free survival
      period compared with patients without HIPEC treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival period</measure>
    <time_frame>Every 3 months up to 30 months</time_frame>
    <description>Every three months until recurrence of disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of overall survival.</measure>
    <time_frame>Every 3 months up to 30 months</time_frame>
    <description>Every three months until recurrence of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of morbidity.</measure>
    <time_frame>Every 3 months up to 30 months</time_frame>
    <description>Every three months until recurrence of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of quality of life related to the procedure.</measure>
    <time_frame>Every 3 months up to 30 months</time_frame>
    <description>Every three months until recurrence of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of Ex vivo correlation.</measure>
    <time_frame>4 days post surgery</time_frame>
    <description>in vitro cell culture to study the effect of temperature and cisplatin on cell viability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Peritoneal Carcinomatosis From Ovarian Cancer</condition>
  <condition>Fallopian Tube Carcinoma</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cytoreduction</intervention_name>
    <description>Cytoreduction</description>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hipec with Cisplatin</intervention_name>
    <description>Intraoperative Intraperitoneal Hyperthermic Chemotherapy (Hipec)+Cisplatin</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Peritoneal carcinomatosis arising from ovarian epithelial carcinoma (stage III or
             higher), carcinoma of the fallopian tube and primary peritoneal carcinoma.

          -  Residual tumor &lt; 2.5 mm after completion of cytoreductive surgery.

          -  Aged &lt; 75 years.

          -  Baseline ECOG 0-1 (Eastern Cooperative Oncologic Group).

          -  Adequate bone marrow function with hemoglobin ? 8 g/dl (after correction for iron
             deficiency anemia), white blood cell count ? 3,000/mm3, platelets ? 100,000/mm3.

          -  Adequate renal function with creatinine ? 1.5 mg/ dl.

          -  Adequate liver function with bilirubin levels ? 1.5 mg / dl and AST and ALT ? 80 IU /
             L.

          -  Optimal cardiopulmonary function.

          -  In recurrences, disease-free interval &gt; 6 months.

          -  Voluntary and signed written informed consent.

        Exclusion Criteria:

          -  Extraperitoneal tumor disease.

          -  Suboptimal debulking (residual tumor &gt; 2.5 mm).

          -  Previous history of other malignancies (excluding skin)

          -  Intestinal obstruction at the time of evaluation.

          -  Renal failure.

          -  Heart failure.

          -  Uncontrolled infection.

          -  Pregnant or lactating patients.

          -  In recurrences, disease-free interval &lt; 6 months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Cascales Campos, M.D Phd</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro Cascales Campos , MD ,PhD</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Cl√≠nico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar.</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Cascales Campos</last_name>
      <phone>968369500</phone>
    </contact>
    <investigator>
      <last_name>Pedro Cascales Campos, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

